Metraipolis › archive › dc_dccacf836e08
Atoltivimab/maftivimab/odesivimab — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/Atoltivimab/maftivimab/odesivimab
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-10T07:24:11.394Z
- SHA-256 of the archived text
149f143c3f3610f153e987b8154efb2b2a081501194d89fa32b069763e5f609e- Stable URL of this page
https://metraipolis.com/documento/dc_dccacf836e08
How to cite
Atoltivimab/maftivimab/odesivimab — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Atoltivimab/maftivimab/odesivimab (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_dccacf836e08 (Metraipolis archive dc_dccacf836e08, sha256 149f143c3f3610f153e987b8154efb2b2a081501194d89fa32b069763e5f609e)
BibTeX
@misc{dcdccacf836e08,
title = {Atoltivimab/maftivimab/odesivimab — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/Atoltivimab/maftivimab/odesivimab},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_dccacf836e08; sha256 149f143c3f3610f153e987b8154efb2b2a081501194d89fa32b069763e5f609e},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Atoltivimab/maftivimab/odesivimab. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Atoltivimab/maftivimab/odesivimab, sold under the brand name INMAZEB, is a fixed-dose combination of three monoclonal antibodies for the treatment of ebola caused by Zaire ebolavirus. It was developed by Regeneron Pharmaceuticals and contains three human monoclonal antibodies, atoltivimab, maftivimab, and odesivimab-ebgn. The most common side effects include fever, chills, tachycardia (fast heart rate), tachypnea (fast breathing), and vomiting; however, these are also common symptoms of Ebola virus infection. Atoltivimab/maftivimab/odesivimab is the first FDA-approved treatment for Zaire ebolavirus. Atoltivimab/maftivimab/odesivimab was approved for medical use in the United States in October 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. It is on the World Health Organization's List of Essential Medicines. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «Atoltivimab/maftivimab/odesivimab» — https://en.wikipedia.org/wiki/Atoltivimab/maftivimab/odesivimab Wikidata Q104863841: «fixed-dose combination of three monoclonal antibodies» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q104863841 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Atoltivimab/maftivimab/odesivimab?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1384436560, consultata il 2026-11-10T07:20:09.584Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 820042f7bebf75a446d02c86d637732d6a54a458b7103b10c8791e1231bf6340